Mifepristone is a highly potent steroidal glucocorticoid receptor (GR) and progesterone receptor (PR) antagonist as well as a moderately potent androgen receptor (AR) antagonist that is not currently approved for the treatment of cancer [11, 12]. This evidence concerns the gene NR3C1 and cancer.